Abstract
Royal jelly is a food for queen and larvae honeybees. 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”) is the principal lipid component in royal jelly. Several pharmacological activities of 10H2DA have been reported: anti-tumor, anti-biotic, immunomodulatory, estrogenic and neurogenic. We recently revealed an inhibitory effect of 10H2DA in innate immune signals. Despite appreciable advances in studies on innate immune signals after the identification of Toll-like receptors as innate immune receptors, few studies have reported the effect of 10H2DA on innate immune signals. In this review, we focus on recent advances in the evaluation of the biological activities of 10H2DA (especially immunomodulatory activities). We also discuss the molecular mechanisms underpinning these biological activities, which could lead to new therapeutic targets for the treatment of immune disorders.
Keywords: Fatty acids, immune disorders, immunomodulator, innate immunity, royal jelly, Toll-like receptors, 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”), propolis, ω-hydroxy lipids, royal jelly protein (MRJP)1, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), innate and adaptive immunity.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Volume: 12 Issue: 4
Author(s): Tsuyoshi Sugiyama, Keita Takahashi and Hiroshi Mori
Affiliation:
Keywords: Fatty acids, immune disorders, immunomodulator, innate immunity, royal jelly, Toll-like receptors, 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”), propolis, ω-hydroxy lipids, royal jelly protein (MRJP)1, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), innate and adaptive immunity.
Abstract: Royal jelly is a food for queen and larvae honeybees. 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”) is the principal lipid component in royal jelly. Several pharmacological activities of 10H2DA have been reported: anti-tumor, anti-biotic, immunomodulatory, estrogenic and neurogenic. We recently revealed an inhibitory effect of 10H2DA in innate immune signals. Despite appreciable advances in studies on innate immune signals after the identification of Toll-like receptors as innate immune receptors, few studies have reported the effect of 10H2DA on innate immune signals. In this review, we focus on recent advances in the evaluation of the biological activities of 10H2DA (especially immunomodulatory activities). We also discuss the molecular mechanisms underpinning these biological activities, which could lead to new therapeutic targets for the treatment of immune disorders.
Export Options
About this article
Cite this article as:
Sugiyama Tsuyoshi, Takahashi Keita and Mori Hiroshi, Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832530
DOI https://dx.doi.org/10.2174/187153012803832530 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Cationicity and Hydrophobicity Enhance the Cytotoxic Potency of Phoratoxin C Anticancer Peptide Analogues against Triple Negative Breast Cancer Cells
Current Bioactive Compounds Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity
Medicinal Chemistry Reviews - Online (Discontinued) Isoindole Derivatives: Propitious Anticancer Structural Motifs
Current Topics in Medicinal Chemistry Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Cytokine Manipulation of the Immune Response in the Treatment of Human Acute Leukaemia
Current Pharmaceutical Design Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics
Current Topics in Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry Low Content of Protein S29 in Ribosomes of Human Lung Cancer Cell Line A549: Detected by Twodimensional Electrophoresis
Protein & Peptide Letters Structure and Ligand-based Design of P-glycoprotein Inhibitors: A Historical Perspective
Current Pharmaceutical Design ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets